Metabolic and Bariatric Surgery · 12 November 2024

Roux-en-Y gastric bypass outperforms sleeve gastrectomy in long-term hypertension remission

A systematic review of 11 randomized controlled trials involving 2,323 patients indicates that both sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) show comparable hypertension remission within the first four years post-surgery. However, RYGB demonstrated a significantly greater effectiveness in achieving remission at five years or more, with a relative risk of 1.39. These findings underscore the long-term advantages of RYGB in hypertension management, aiding surgical decision-making and patient counseling.

Journal Article by Zevallos A, Sanches EE (…) Pouwels S et 2 al. in Surg Obes Relat Dis

read the whole article in Surg Obes Relat Dis

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Metabolic and Bariatric Surgery.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

The latest stitches

Surg Endosc29 Sep 2026

Endoscopic Sleeve Gastroplasty Offers Safer Alternative to LSG

Endoscopic sleeve gastroplasty (ESG) provides moderate weight loss with a lower risk of complications compared to laparoscopic sleeve gastrectomy (LSG), making it a viable option for patients, particularly those with existing gastro-esophageal reflux disease (GERD).

Ann Surg13 Jul 2026

Predictive Models Enhance Diabetes Remission After Surgery

A new calculator predicts type 2 diabetes remission outcomes for patients post-metabolic surgery, improving patient selection.

Ann Surg16 Jun 2026

EndoBarrier Shows Promise for Type 2 Diabetes in Obesity

Endoscopic duodenal-jejunal bypass liner may significantly improve glycemic control and weight loss in patients with poorly controlled type 2 diabetes and obesity.

All papers in Metabolic and Bariatric Surgery →